357 related articles for article (PubMed ID: 35300705)
1. Dual effect of TAT functionalized DHAH lipid nanoparticles with neurotrophic factors in human BBB and microglia cultures.
Hernando S; Nikolakopoulou P; Voulgaris D; Hernandez RM; Igartua M; Herland A
Fluids Barriers CNS; 2022 Mar; 19(1):22. PubMed ID: 35300705
[TBL] [Abstract][Full Text] [Related]
2. Nanostructured Lipid Carriers Made of Ω-3 Polyunsaturated Fatty Acids: In Vitro Evaluation of Emerging Nanocarriers to Treat Neurodegenerative Diseases.
Hernando S; Herran E; Hernandez RM; Igartua M
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33003360
[TBL] [Abstract][Full Text] [Related]
3. Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.
Hernando S; Herran E; Figueiro-Silva J; Pedraz JL; Igartua M; Carro E; Hernandez RM
Mol Neurobiol; 2018 Jan; 55(1):145-155. PubMed ID: 28866799
[TBL] [Abstract][Full Text] [Related]
4. Microfluidic blood-brain barrier model provides in vivo-like barrier properties for drug permeability screening.
Wang YI; Abaci HE; Shuler ML
Biotechnol Bioeng; 2017 Jan; 114(1):184-194. PubMed ID: 27399645
[TBL] [Abstract][Full Text] [Related]
5. Generation of an hiPSC-Derived Co-Culture System to Assess the Effects of Neuroinflammation on Blood-Brain Barrier Integrity.
Bull D; Schweitzer C; Bichsel C; Britschgi M; Gutbier S
Cells; 2022 Jan; 11(3):. PubMed ID: 35159229
[TBL] [Abstract][Full Text] [Related]
6. Microglia-derived HIV Nef+ exosome impairment of the blood-brain barrier is treatable by nanomedicine-based delivery of Nef peptides.
Raymond AD; Diaz P; Chevelon S; Agudelo M; Yndart-Arias A; Ding H; Kaushik A; Jayant RD; Nikkhah-Moshaie R; Roy U; Pilakka-Kanthikeel S; Nair MP
J Neurovirol; 2016 Apr; 22(2):129-39. PubMed ID: 26631079
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 Tat disrupts blood-brain barrier integrity and increases phagocytic perivascular macrophages and microglia in the dorsal striatum of transgenic mice.
Leibrand CR; Paris JJ; Ghandour MS; Knapp PE; Kim WK; Hauser KF; McRae M
Neurosci Lett; 2017 Feb; 640():136-143. PubMed ID: 28057474
[TBL] [Abstract][Full Text] [Related]
8. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model.
Clark PA; Al-Ahmad AJ; Qian T; Zhang RR; Wilson HK; Weichert JP; Palecek SP; Kuo JS; Shusta EV
Mol Pharm; 2016 Sep; 13(9):3341-9. PubMed ID: 27421304
[TBL] [Abstract][Full Text] [Related]
10. Cryopreservation of Brain Endothelial Cells Derived from Human Induced Pluripotent Stem Cells Is Enhanced by Rho-Associated Coiled Coil-Containing Kinase Inhibition.
Wilson HK; Faubion MG; Hjortness MK; Palecek SP; Shusta EV
Tissue Eng Part C Methods; 2016 Dec; 22(12):1085-1094. PubMed ID: 27846787
[TBL] [Abstract][Full Text] [Related]
11. Development of Human in vitro Brain-blood Barrier Model from Induced Pluripotent Stem Cell-derived Endothelial Cells to Predict the in vivo Permeability of Drugs.
Li Y; Sun X; Liu H; Huang L; Meng G; Ding Y; Su W; Lu J; Gong S; Terstappen GC; Zhang R; Zhang W
Neurosci Bull; 2019 Dec; 35(6):996-1010. PubMed ID: 31079318
[TBL] [Abstract][Full Text] [Related]
12. Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells.
Hollmann EK; Bailey AK; Potharazu AV; Neely MD; Bowman AB; Lippmann ES
Fluids Barriers CNS; 2017 Apr; 14(1):9. PubMed ID: 28407791
[TBL] [Abstract][Full Text] [Related]
13. Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models.
Zwain T; Alder JE; Sabagh B; Shaw A; Burrow AJ; Singh KK
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111774. PubMed ID: 33579439
[TBL] [Abstract][Full Text] [Related]
14. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers.
Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H
J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054
[TBL] [Abstract][Full Text] [Related]
15. Involvement of Microglia in Neurodegenerative Diseases: Beneficial Effects of Docosahexahenoic Acid (DHA) Supplied by Food or Combined with Nanoparticles.
Charrière K; Ghzaiel I; Lizard G; Vejux A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638979
[TBL] [Abstract][Full Text] [Related]
16. Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy.
Wang H; Sun G; Zhang Z; Ou Y
Biomed Pharmacother; 2017 Jul; 91():241-250. PubMed ID: 28460227
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit.
Banks WA; Gray AM; Erickson MA; Salameh TS; Damodarasamy M; Sheibani N; Meabon JS; Wing EE; Morofuji Y; Cook DG; Reed MJ
J Neuroinflammation; 2015 Nov; 12():223. PubMed ID: 26608623
[TBL] [Abstract][Full Text] [Related]
18. Transferrin-functionalized lipid nanoparticles for curcumin brain delivery.
Neves AR; van der Putten L; Queiroz JF; Pinheiro M; Reis S
J Biotechnol; 2021 Apr; 331():108-117. PubMed ID: 33727082
[TBL] [Abstract][Full Text] [Related]
19. Engineered Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as New Generations of Blood-Brain Barrier Transmitters.
Amiri M; Jafari S; Kurd M; Mohamadpour H; Khayati M; Ghobadinezhad F; Tavallaei O; Derakhshankhah H; Sadegh Malvajerd S; Izadi Z
ACS Chem Neurosci; 2021 Dec; 12(24):4475-4490. PubMed ID: 34841846
[TBL] [Abstract][Full Text] [Related]
20. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
